SCHEMBL11027433

SCHEMBL11027433

CN1CCN(c2ccc(Nc3cc(-c4cccc(Cl)c4)cnc3C(N)=O)cc2)CC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPKAPK2 P49137 5/20 0.60
▸ SLC2A1 P11166 2/20 0.55
▸ RAD52 P43351 1/20 0.49
▸ GFER P55789 1/20 0.49
▸ JAK2 O60674 2/20 0.49
▸ JAK1 P23458 1/20 0.49
▸ TYK2 P29597 1/20 0.49
▸ JAK3 P52333 1/20 0.49
▸ LCK P06239 1/20 0.48
▸ MAPK14 Q16539 1/20 0.48
▸ BTK Q06187 2/20 0.48
▸ EGFR P00533 2/20 0.48
▸ HDAC3 O15379 1/20 0.47
▸ HDAC2 Q92769 1/20 0.47
▸ AURKA O14965 1/20 0.46
▸ CDK2 P24941 1/20 0.46
▸ CSF1R P07333 2/20 0.46
▸ CCNT1 O60563 1/20 0.46
▸ CDK4 P11802 1/20 0.46
▸ CCND1 P24385 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11029599 0.90 MAPKAPK2 (0.58) MAPKAPK2SLC2A1BTKEGFRHDAC3
SCHEMBL11031445 0.89 SLC2A1 (0.51) MAPKAPK2SLC2A1RAD52BTKEGFR
SCHEMBL11029346 0.89 MAPKAPK2 (0.61) MAPKAPK2SLC2A1BTKEGFRHDAC3
SCHEMBL11026741 0.89 FYN (0.55) MAPKAPK2SLC2A1BTKEGFRAURKA
SCHEMBL11030051 0.86 SLC2A1 (0.57) MAPKAPK2SLC2A1EGFRAURKACDK2
SCHEMBL11031519 0.86 SLC2A1 (0.57) MAPKAPK2SLC2A1JAK2JAK1TYK2
SCHEMBL11029146 0.86 SLC2A1 (0.49) MAPKAPK2SLC2A1EGFRAURKACDK2
SCHEMBL11029481 0.85 SLC2A1 (0.52) MAPKAPK2SLC2A1RAD52GFERJAK2
SCHEMBL11031045 0.85 RAD52 (0.55) MAPKAPK2SLC2A1RAD52BTKEGFR
SCHEMBL11030640 0.85 PTK2 (0.59) MAPKAPK2SLC2A1JAK2JAK1TYK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8859546-B2 Picolinamide inhibitors of kinases ABBVIE INC. (US) 2014-10-14 — — US claimed
EP-2665711-A1 PICOLINAMIDE INHIBITORS OF KINASES Abbvie Inc. (US) 2013-11-27 — — EP claimed
CN-103380117-A Picolinamide inhibitors of kinases ABBOTT LAB 2013-10-30 — — CN claimed
WO-2012100135-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 — — WO claimed
US-20120190681-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 — — US claimed
US-8859546-B2 Picolinamide inhibitors of kinases ABBVIE INC. (US) 2014-10-14 — — US disclosed
EP-2665711-A1 PICOLINAMIDE INHIBITORS OF KINASES Abbvie Inc. (US) 2013-11-27 — — EP disclosed
CN-103380117-A Picolinamide inhibitors of kinases ABBOTT LAB 2013-10-30 — — CN disclosed
US-20120190681-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 — — US disclosed
WO-2012100135-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190681-A1 PICOLINAMIDE INHIBITORS OF KINASES ALK, PKN2, ERBB2 MAPKAPK2 115/4885SLC2A1 3662/4885RAD52 4739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback